ECM
TTNP

ETrade Capital Management’s Titan Pharmaceuticals TTNP Stock Holding History

ETrade Capital Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-102
Closed -$14K – 908
2020
Q1 		$14K Buy
102
+85
+500% +$13.3K ﹤0.01% 748
2019
Q4 		$2K Buy
+17
New +$2.05K ﹤0.01% 785

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

ETrade Capital Management's TTNP Position: Q2 2020 in Review

ETrade Capital Management sold out of Titan Pharmaceuticals (TTNP) in Q2 2020, closing a stake of 102 shares — an estimated $14K sold.

ETrade Capital Management first reported a position in TTNP in Q4 2019 and held it in 2 quarters. The position peaked at $14K in Q1 2020. 23 funds tracked by Wall St. Rank hold TTNP as of Q2 2020.

  • ETrade Capital Management reported no remaining Titan Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • ETrade Capital Management sold 102 Titan Pharmaceuticals shares in Q2 2020, an estimated $14K.
  • ETrade Capital Management first reported a position in Titan Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • ETrade Capital Management's Titan Pharmaceuticals position peaked at $14K in Q1 2020.
  • 23 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2020.

Based on ETrade Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.